Hongkun Wang
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
TMC6 Is a Novel Therapeutic Target for Pathogenic Cardiac Hypertrophy.
Journal: Circulation research
Published: February 25, 2026
Decreased RYR2 Cluster Size and Abnormal SR Ca2+ Release Contribute to Arrhythmogenesis in TMEM43-Related ARVC.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: June 30, 2025
A simple and standardized method supports efficient derivation of clinical-grade human embryonic stem cells under feeder- and xeno-free conditions.
Journal: Stem cell research & therapy
Published: May 03, 2025
Overexpression of KCNJ2 enhances maturation of human-induced pluripotent stem cell-derived cardiomyocytes.
Journal: Stem cell research & therapy
Published: August 11, 2022
Establishment of an induced pluripotent stem cell line (ZJULLi004-A) from a hypertrophic cardiomyopathy patient carrying MYBPC3/c.3764C>A mutation.
Journal: Stem cell research
Published: August 11, 2022
Generation of an induced pluripotent stem cell line (ZJULLi003-A) from a hypertrophic cardiomyopathy patient carrying MYH7/c.4384G > A mutation.
Journal: Stem cell research
Published: June 30, 2022
Hyperactivation of platelet-derived growth factor signalling contributes to arrhythmogenesis in Brugada syndrome.
Journal: Clinical and translational medicine
Published: October 29, 2021
Corrigendum to "Reprogramming of human peripheral blood mononuclear cells from a patient suffering from recurrent hydatidiform mole to an iPSC line FAHZUi001-A carrying a homozygous p.Gln421Ter mutation in NLRP7 gene" [Stem Cell Res. 53 (2021) 102361].
Journal: Stem cell research
Published: July 30, 2021
Inhibition of HSC70 alleviates hypertrophic cardiomyopathy pathology in human induced pluripotent stem cell-derived cardiomyocytes with a MYBPC3 mutation.
Journal: Clinical and translational medicine
Published: July 30, 2021
Last Updated: 09/26/2026